Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Dravet syndrome, a rare and severe form of epilepsy, presents significant challenges for patients, families, and caregivers, including multiple seizures per day and substantial developmental ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...

"Dravet Syndrome, seizures and what goes along with it usually changes every year," Nicole Watson said. Because it's so rare, research and treatments are limited and Nicole Watson is working to ...